Congress Letters from Senator Grassley: University of Wisconsin Provide More Details… Thomas Sullivan Jan 20, 2009 1 Doctor paid millions… This is a statement we have seen in newspapers across the country about the difference in what a…
Academic Organizations AAMC: CME Report from Bermuda to Monaco – More from the Ivory Tower Thomas Sullivan Jan 19, 2009 1 …
State Policy State Policy: Virginia Delegate Files Ban on Prescription Commercial Data Thomas Sullivan Jan 19, 2009 0 Virginia Assembly Delegate, Mark D. Sickles (Dem., Springfield), a proponent of bringing investment in Bio Tech and Biosciences…
Pharmaceutical and Device Eli Lilly: Settles for 1.4 Billion, Now the Details Thomas Sullivan Jan 16, 2009 0 Eli Lilly agreed to pay $1.4 Billion to the U.S. government to settle criminal and civil cases surrounding the promotion of…
Institute of Medicine IOM: ACCME Testimony – IOM – Try Again Thomas Sullivan Jan 15, 2009 0 The ACCME does believe that an enhanced research enterprise can help ACCME meet its mission – but we are not sure that any…
State Policy State Policy: Texas introduces Two Transparency Bills “Everybody Loves… Thomas Sullivan Jan 14, 2009 0 ”Everybody loves Transparency - this was the theme of a recent Dallas Morning News article outlining two transparency bills SB…
Congress Grassley: GSK Avandia Email Report — Looking Over Your Shoulder Thomas Sullivan Jan 14, 2009 0 According to The Wall Street Journal, coming soon to your local newspaper is a report from Senator Grassley on e-mails his staff…
Government Agencies FDA: Issues Guidance on Journal Reprints Thomas Sullivan Jan 14, 2009 0 In a move that has many wondering where it came from (as it was not on the Bush list of priorities prior to leaving office),…
Healthcare Reform Health Care Reform: Kennedy Legacy to Speed Process Thomas Sullivan Jan 13, 2009 0 Senator Edward Kennedy’s health has transformed President-elect Barack Obama’s plan to reform national healthcare into a legacy…
Government Agencies FDA: Vytorin Scare a False Alarm Thomas Sullivan Jan 13, 2009 0 After a one-year safety review of Vytorin, the FDA announced that patients should stay on Vytorin therapy. According to the FDA…